Nimotuzumab Improves OS, PFS in KRAS Wild-Type Advanced Pancreatic Cancer
Adding nimotuzumab to treatment with gemcitabine improves survival outcomes in patients with KRAS wild-type advanced pancreatic cancer, a phase 3 trial suggests.
Pancreatic Cancer News
PANCREATIC CANCER ADVISOR
Pancreatic Cancer News
The Challenge of Making Cancer Trials More Diverse
Patients from racial and ethnic minority groups are still underrepresented in cancer research, despite efforts to make clinical trials more diverse.
High Prevalence of BRCA2 Variants in Pancreatic Acinar Cell Carcinoma
In a pan-cancer analysis, patients with pancreatic acinar cell carcinoma had the highest prevalence of BRCA2 germline pathogenic variants.
Divarasib Shows Activity in Patients With KRAS-Mutated Solid Tumors
Divarasib produced responses in patients with non-small cell lung cancer, colorectal cancer, and other solid tumors in a phase 1 trial.
Smoking May Reduce Survival Benefit of Neoadjuvant FOLFIRINOX in Pancreatic Cancer
Active smoking is associated with shorter overall survival in pancreatic cancer patients treated with neoadjuvant FOLFIRINOX, a study suggests.
Lorazepam Use Linked to Shorter PFS, OS in Several Cancers
Lorazepam use may impact progression-free survival and overall survival in patients with a range of cancers, new research suggests.
Black, Hispanic Patients Have Higher Risk of Death From Second Primary Cancers
Black and Hispanic patients have a higher risk of death from second primary cancers than White and Asian/Pacific Islander patients, new data suggest.
SeekInCare Blood Test Can Detect More Than 20 Cancer Types
SeekInCare, a blood-based multi-cancer detection test, can detect more than 20 cancer types with high specificity, according to researchers.
Surgery May Be Underused in Pancreatic Cancer
A study of patients in Texas suggests that surgery is underutilized for the treatment of resectable pancreatic ductal adenocarcinoma.
Cancer Mortality in Hispanic Patients Decreasing Overall, Increasing for Certain Cancers
Hispanic patients have seen increases in cancer-specific mortality for certain cancers, including liver, pancreatic, and uterine cancer.
ASCO 2023: Will Gastrointestinal Cancer Studies Affect Practice?
Research presented at ASCO 2023 highlights the latest developments in gastrointestinal cancer treatment.
How to Treat Gastrointestinal Cancers During the Chemotherapy Shortage
ASCO has released recommendations outlining how to treat patients with gastrointestinal cancer while chemotherapy drugs are in short supply.
NALIRIFOX Deemed New Reference Regimen for Untreated Metastatic PDAC
NALIRIFOX can improve survival vs gemcitabine plus nab-paclitaxel in patients with previously untreated, metastatic pancreatic ductal adenocarcinoma, a phase 3 trial suggests.
Neoadjuvant FOLFIRINOX Does Not Improve OS in Resectable Pancreatic Cancer
Neoadjuvant FOLFIRINOX does not provide a survival benefit over upfront surgery in resectable pancreatic cancer, a phase 2 study suggests.
Neuroblastoma Survivors Report Neurocognitive Impairment, Failure to Reach Milestones
Survivors of childhood neuroblastoma have neurocognitive impairments that affect their ability to reach adult milestones, a study suggests.
BMI Over Time Tied to Risk of CRC and Other GI Cancers
Patients who are overweight or obese in early, middle, or late adulthood may have an increased risk of gastrointestinal cancers, a study suggests.
Sex Hormones Linked to Risk of Gastrointestinal Cancers
Higher levels of certain sex hormones are associated with an increased risk of some gastrointestinal cancers, a meta-analysis suggests.
NAFLD Linked to Higher Risk of Young-Onset Digestive Tract Cancers
Nonalcoholic fatty liver disease is associated with an increased risk of young-onset digestive tract cancers, a study suggests.
Adagrasib Shows Activity in Hard-to-Treat KRAS-Mutated Solid Tumors
Adagrasib produced responses in a phase 1/2 trial of patients with heavily pretreated, KRAS G12C-mutated solid tumors.
Camonsertib-PARP Inhibitor Combos May Meet Unmet Need in Advanced Solid Tumors
Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Pancreatic Cancer
Loading... 
Loading...